Christopher Clayton Porter MD

PubMed

• 1 citations
  Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders.
  Yoshiko Nakano, Roland P Kuiper, Kim E Nichols, Christopher C Porter, Harry Lesmana
  Clinical Cancer Research. 2024-11-15
• 1 citations
  Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group.
  Suzanne P MacFarland, Kerri Becktell, Kami Wolfe Schneider, Roland P Kuiper, Harry Lesmana
  Clinical Cancer Research. 2024-10-15
• Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy.
  Luke D Maese, Marcin W Wlodarski, Sun Young Kim, Alison A Bertuch, Gaelle Bougeard
  Clinical Cancer Research. 2024-10-01

Journal Articles

• Irradiation selects for p53 mutation in hematopoietic progenitors  
  Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J, PLoS Biology, 1/1/2010
• Bcl-6 over-expression correlates with monomorphic histology in children with post-transplantation lymphoproliferative disease  
  Porter CC, Liang X, Gralla J, McGavran L, Albano EA, J Pediatr Hematol/Oncol, 1/1/2008

Books/Book Chapters

• Current Pediatric Diagnosis and Treatment. 
  Chapter: Neoplastic Diseases. 
  Albano EA, Basal M, Porter CC, Foreman NK, Stork LEditors: Hay WW, Levin MJ, Sondheimer JM and RR Deterding.Appleton and Lange, New York, NYEdition 17th,2005

Abstracts/Posters

• Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes
  Christopher C. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ETV6 represses Pax5 in early B cell development.
  Jones CL, Kirkpatrick G, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Rowley J, Di Paola J, Hagman JR, Porter CC, Blood, 1/1/2016
• IFN-y Alters the Expression of Diverse Immunity Related Genes in a Cell Culture Model of Maturing Bone Marrow Neutrophils.
  Ellison MA, Gearheart CM, Porter CC and Ambruso DR, Blood, 1/1/2016
• ETV6 represses Pax5 in early B cell development.
  Jones CL, Kirkpatrick G, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Rowley J, Di Paola J, Hagman JR, Porter CC, American Society of Hematology Annual Meeting, 1/1/2016
• IFN-? Alters the Expression of Diverse Immunity Related Genes in a Cell Culture Model of Maturing Bone Marrow Neutrophils.
  Ellison MA, Gearheart CM, Porter CC and Ambruso DR, American Society of Hematology Annual Meeting, 1/1/2016
• ETV6 represses PAX5 expression in early B cell development.
  Jones CL, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Di Paola J, Hagman JR, Porter CC, American Association for Cancer Research Annual Meeting, 1/1/2016
• Combined inhibition of WEE1 and PARP1/2 synergistically inhibits acute leukemia cells by enhancing DNA damage and inducing apoptosis in vitro and in vivo.
  Garcia TB, Snedeker, JC, Porter CC, American Association for Cancer Research Annual Meeting, 1/1/2016
• Inhibition of leukemia-cell calcineurin promotes T cell-mediated suppression of leukemogenesis.
  Gardner L, Lee-Miller CA, Rabe J, Leibowitz M, Gearheart C, Patel A, Slansky J, Porter CC, Pediatr Blood Cancer; American Society of Pediatric HematologyOncology Annual Meeting, 1/1/2015
• A dominant negative mutation (p.P214L) in ETV6 is associated with megakaryocyte and erythroid transcript misregulation.
  Noetzli L, Rowley JW, Callaghan MU, Rajpurkar M, Lee-Sherick AB, Porter CC, Weyrich AS, Di Paola JA, Blood, 1/1/2015
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Pediatric Blood and Cancer, 1/1/2014
• PTP4A3 is oncogenic and modulates triple negative breast cancer growth.
  Gari HH, Ray R, Lucia S, Porter CC, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Ru Y, Thor AD, Lambert JR, American Association for Cancer Research Annual Meeting, 1/1/2014
• MAPK signaling cascades mediate distinct prednisolone resistance mechanisms in pediatric pre-B ALL.
  Jones CL, Gearheart CM, Fosmire S, Delgado-Martin, C, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Raetz EA, Hermiston ML, Garabedian M..., American Society of Hematology Annual Meeting, 1/1/2014
• Combined inhibition of Wee1 and PARP1/2 synergistically inhibits AML cells by enhancing DNA damage and the induction of apoptosis.
  Snedeker J, Burleson T, Tibes R, Porter CC, American Society of Hematology Annual Meeting, 1/1/2014
• MAPK signaling cascades mediate distinct prednisolone resistance mechanisms in pediatric pre-B ALL.
  Jones CL, Gearheart CM, Fosmire S, Delgado-Martin, C, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Raetz EA, Hermiston ML, Garabedian M..., Blood, 1/1/2014
• Combined inhibition of Wee1 and PARP1/2 synergistically inhibits AML cells by enhancing DNA damage and the induction of apoptosis.
  Snedeker J, Burleson T, Tibes R, Porter CC, Blood, 1/1/2014
• Leukemia-cell calcineurin mediates immune evasion independent of clinically relevant modulators of the immune response.
  Patel A, Gardner L, Porter CC, Student Cancer Research Fellowship Program Poster Session, University of Colorado Cancer Center, 1/1/2014
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Department of Pediatrics, Spring Poster Session, Children's Hospital Colorado/ University of Colorado School of Medicine, 1/1/2013
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Pediatric Blood and Cancer; American Society of Pediatric Hematology-Oncology Annual Meeting, 1/1/2013
• Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway in Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
  Jones CL, Gearheart CM, Fosmire S, Wang J, Bitterman DS, Bhatla T, Bourgeois, Porter CC, Carroll WL, Blood; American Society of Hematology Annual Meeting, 1/1/2013
• Inhibition of Wee1 enhances the anti-leukemic effects of antimetabolites in vitro and in vivo.
  Ford J, Baturin D, Van Linden A, Fosmire S, Porter CC, Blood; American Society of Hematology Annual Meeting, 1/1/2013
• Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway in Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
  Jones CL, Gearheart CM, Fosmire S, Wang J, Bitterman DS, Bhatla T, Bourgeois, Porter CC, Carroll WL, Blood, 1/1/2013
• Inhibition of Wee1 enhances the anti-leukemic effects of antimetabolites in vitro and in vivo.
  Ford J, Baturin D, Van Linden A, Fosmire S, Porter CC, Blood, 1/1/2013
• Functional genomic screening to identify novel therapeutic targets in IKZF1 mutated ALL.
  Fosmire S, Ford J, Gearheart C, Porter CC, The Future of Pediatric Oncology: From Targets to Treatments Symposium, Washington, DC, 1/1/2013
• Deciphering an autophagy-dependent gene expression signature indicative of longterm prognosis for pediatric ependymoma patients.
  Gearheart CM, Birks D, Donson A, Tan AC, Forman N, Porter CC, Mulcahy-Levy J, Postdoctoral Research Poster Session, University of Colorado Denver, 1/1/2013
• A genome-wide screen identified the WNT pathway as a potential target for combination treatments with BRAF inhibitors in melanoma.
  Almeida AR, Partyka KA, Tan AC, Kim J, Porter CC, Casas-Selves M, Gregory MA, Smith S, Fujita M, DeGregori J, Norris DA, Shellman YG, J Invest Derm; Annual Society of Investigative Dermatology Meeting, 1/1/2012
• Join now to see all

Lectures

• Cancer and the immune system. 
  1/1/2016
• Introduction to hematopoietic malignancies 
  1/1/2016
• Chronic myeloid leukemia 
  1/1/2016
• Germline mutations associated with leukemia. 
  San Diego, CA - 1/1/2016
• Molecular mechanisms of leukemogenesis and treatment resistance. 
  Emory University School of Public Health, Atlanta, GA - 1/1/2016
• Defining the impact of trisomy 21 on the immune cell repertoire and function. 
  Boulder, CO - 1/1/2016
• What's old is new again: familiar proteins with novel roles in leukemogenesis. 
  Emory University, Atlanta, GA - 1/1/2015
• A dominant negative mutation (p.P214L) in ETV6 is associated with megakaryocyte and erythroid transcript misregulation. 
  1/1/2015
• Calcineurin drives immune evasion during leukemogenesis. 
  Vail, CO - 1/1/2015
• Balancing Work/Life and Clinical/Research Effort. 
  University of Colorado School of Medicine, Aurora, CO - 1/1/2015
• Calcineurin promotes immune evasion during leukemogenesis. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2015
• Flow cytometry shared resource. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2015
• Development of Wee1 as a therapeutic target for leukemia. 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2015
• Childhood Leukemia and Lymphoma. 
  Aurora, CO - 1/1/2015
• Leukemia-cell calcineurin mediates a potent immune suppressive mechanism during leukemogenesis. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2014
• Leukemia-cell calcineurin mediates a potent immune evasion mechanism. 
  Aurora, CO - 1/1/2014
• Developing novel therapies for childhood leukemia. 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2014
• Leukemia-cell calcineurin mediated immune evasion in leukemogenesis 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2014
• RNAi screens to identify novel therapeutic strategies for leukemia: going all the way. 
  Baltimore, MD - 1/1/2014
• Identification of molecular vulnerabilities in pre-B cells with Ikaros dysfunction. 
  Washington, DC - 1/1/2014
• Pediatric Cancer: Progress and Challenge. 
  Aurora, CO - 1/1/2014
• Immune and cell cycle checkpoints in leukemogenesis and treatment failure. 
  University of Colorado Denver, Aurora, CO - 1/1/2014
• Development of Wee1 as a therapeutic targe in ALL. 
  Lexington, KY - 1/1/2014
• Therapeutic inhibition of Wee1 for leukemia 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2013
• Validation and identification of novel therapeutic targets in ALL. 
  Los Angeles, CA - 1/1/2013
• Join now to see all

Other

• Germline mutations associated with leukemias. (Invited Review) 
  Porter CC, Hematology, American Society of Hematology Education Program
  1/1/2016
• Back to the Bedside. 
  Porter CC, ASH News Daily
  1/7/2010
• The promise of gene therapy that WAS is now. 
  CC Porter, ASH News Daily
  1/6/2010
• Inside information: insight on health-care reform from a White House advisor. 
  Porter CC, ASH News Daily
  1/6/2010
• Big Hematology: Large-scale collaborations asking genome-scale questions. 
  Porter CC, ASH News Daily
  1/5/2010
• Leukemia Stem Cells: Answers and More Questions. 
  Porter CC, ASH News Daily
  1/5/2010
• Join now to see all